Talk:Lapatinib

From Wikipedia, the free encyclopedia

	Lapatinib is part of WikiProject Pharmacology, a project to improve all Pharmacology-related articles. If you would like to help improve this and other pharmacology articles, please join the project. All interested editors are welcome.
Stub	This article has been rated as stub-Class on the quality scale.

	This article is within the scope of WikiProject Medicine. Please visit the project page for details or ask questions at the doctor's mess.
Stub	This page has been rated as Stub-Class on the quality assessment scale
Mid	This article has been rated as Mid-importance on the importance assessment scale

[edit] The

"The exact site of binding has currently not been confirmed (EGFR and ErbB2 have a number of intracellular phosphorylation sites)."

-- this should probably be removed, at least for EGFR, since there's a crystal structure of Lapatinib bound to the ATP binding site from 2004: pdb code 1XKK.

Lapatinib is well known as an ATP-competitive kinase inhibitor (that was determined well before the crystal structure being solved). The comment has been removed. 05:52, 18 December 2007 (UTC)btavshan

Its identity as a kinase inhibitor is explicated in the third paragraph, if that wasn't obvious enough from the name. Could you point to when/where/what was actually removed? Otherwise, I can't tell if any information is missing that could go in there. Someguy1221 (talk) 05:57, 18 December 2007 (UTC)